CXCL3 promotes liver cancer progression by modulating the tumor microenvironment via the PI3K/AKT/mTOR pathway
Yue Li, Tao Liu, Ziteng Cai, Chaonan Peng, Zhilei He, Lichun Liang, Bo Han, Ran Bi, Lei Liu, Weiqun Wang
TL;DR
CXCL3 promotes liver cancer by altering the tumor environment and activating the PI3K/AKT/mTOR pathway, leading to faster tumor growth and worse patient outcomes.
Contribution
This study reveals a novel role of CXCL3 in liver cancer progression through microenvironment modulation and pathway activation.
Findings
CXCL3 is upregulated in liver cancer and linked to reduced patient survival.
CXCL3 activates the PI3K/AKT/mTOR pathway and promotes tumor cell growth and migration.
CXCL3 overexpression in mice significantly increases tumor growth.
Abstract
CXCL3, a member of the CXC chemokine family, has been increasingly implicated in the progression of various cancers, including hepatocellular carcinoma, due to its role in immune and inflammatory responses within the tumor microenvironment. This study aimed to investigate the expression and function of CXCL3 in liver cancer and to elucidate its underlying mechanisms. A combination of bioinformatics analysis, ELISA, RT-qPCR, immunohistochemistry, in vitro cell assays, and in vivo nude mouse models was employed to assess CXCL3 expression and function. The results showed that CXCL3 was significantly upregulated in hepatocellular carcinoma tissues and associated with reduced overall survival in patients. It promoted the proliferation, colony formation, and migration of liver cancer cells (Bel-7402, HepG2, and SMMC-7721) via exogenous, autocrine, and paracrine mechanisms, and recruited…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChemokine receptors and signaling · Immune cells in cancer · Cancer Immunotherapy and Biomarkers